Advertisement
YOU ARE HERE: LAT HomeCollectionsHana Biologics Inc
IN THE NEWS

Hana Biologics Inc

FEATURED ARTICLES
BUSINESS
January 12, 1989 | From States News Service
Montgomery Medical Ventures II acquired the equivalent of a 23.2% stake in Alameda, Calif.-based Hana Biologics Inc., according to a filing with the Securities and Exchange Commission. Montgomery Medical, a venture capital fund created to make investments, bought 60,000 series A preferred shares that are convertible into about 1 million common shares. A warrant to buy 16.7 common shares was granted to Montgomery Medical for each preferred share it purchased.
ARTICLES BY DATE
BUSINESS
September 20, 1989 | Leslie Berkman, Times staff writer
Irvine Scientific, a biotechnology supply company in Santa Ana, has bought the cell biology and diagnostic product lines of Hana Biologics, a biotechnology company in Alameda, for $14.4 million. The acquisition is expected to complement Irvine Scientific's existing products, used by biotechnology companies and research universities and hospitals.
Advertisement
BUSINESS
September 20, 1989 | Leslie Berkman, Times staff writer
Irvine Scientific, a biotechnology supply company in Santa Ana, has bought the cell biology and diagnostic product lines of Hana Biologics, a biotechnology company in Alameda, for $14.4 million. The acquisition is expected to complement Irvine Scientific's existing products, used by biotechnology companies and research universities and hospitals.
BUSINESS
January 12, 1989 | From States News Service
Montgomery Medical Ventures II acquired the equivalent of a 23.2% stake in Alameda, Calif.-based Hana Biologics Inc., according to a filing with the Securities and Exchange Commission. Montgomery Medical, a venture capital fund created to make investments, bought 60,000 series A preferred shares that are convertible into about 1 million common shares. A warrant to buy 16.7 common shares was granted to Montgomery Medical for each preferred share it purchased.
BUSINESS
December 2, 1987
Charles Crocker has been elected chairman of Hana Biologics Inc., Alameda. Crocker, 48, succeeds Robert Berkowitz, who resigned because of new responsibilities as president and chief executive of CytoSciences Inc. Crocker, a co-founder of the company, has been chairman or co-chairman from the company's founding until January, 1986. Berkowitz will continue as a Hana director.
NEWS
September 18, 1985 | ANDREW C. REVKIN, Times Staff Writer
Scientists in Denver have transplanted pancreas tissue from aborted human fetuses into three diabetics within the last year, marking the first time in this country that fetal tissue has been used to treat an illness. The trials are designed to test a highly experimental treatment for the most serious form of diabetes, which generally appears before the 20th birthday. If they work, more than a million people may reap dramatic benefits.
NEWS
April 16, 1988 | THOMAS H. MAUGH II, Times Science Writer
When diabetic Rich Shultz received a transplant of pancreatic cells taken from an aborted human fetus two years ago, the Santa Barbara man became a participant in a fast-growing but controversial field of experimental therapy. Many biomedical researchers believe that fetal tissues and cells have enormous potential for helping hundreds of thousands of people with hormone-deficiency disorders such as Parkinson's, Huntington's and Alzheimer's diseases, as well as diabetes.
Los Angeles Times Articles
|